The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

In the past year, treatments such as Wegovy, Mounjaro and Zepbound have become household names. But there are many questions ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

The rise of these medications is causing many patients to experience what's now commonly known as 'Ozempic face,' a term coined by New York-based dermatologist Paul Jarrod Frank, MD that refers to the ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

In the case of breast cancer, women with a higher BMI do have higher rates of recurrence compared to women in the "normal" ...

A new study has found that a once-weekly injection of semaglutide, a medication originally developed for diabetes and weight ...